Lucía López, Luciano Gastón Morosi, Federica La Terza, Pierre Bourdely, Giuseppe Rospo, Roberto Amadio, Giulia Maria Piperno, Valentina Russo, Camilla Volponi, Simone Vodret, Sonal Joshi, Francesca Giannese, Dejan Lazarevic, Giovanni Germano, Patrizia Stoitzner, Alberto Bardelli, Marc Dalod, Luigia Pace, Nicoletta Caronni, Pierre Guermonprez, Federica Benvenuti
Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses to model antigens, in various tumor settings. However, the impact of cross-presenting cDC1 and the potential of DC-based therapies in tumors carrying varied levels of bona-fide neoantigens (neoAgs) remain unclear. Here we develop a hypermutated model of non-small cell lung cancer in female mice, encoding genuine MHC-I neoepitopes to study neoAgs-specific CD8 T cell responses in spontaneous settings and upon Flt3L + αCD40 (DC-therapy)...
March 13, 2024: Nature Communications